Loading
Every dated change on the records linked to Neuroblastoma (paediatric), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Tandem autologous transplant (thiotepa-cyclophosphamide, then CEM) in North America (ANBL0532); single busulfan-melphalan transplant in Europe (HR-NBL1). (NCCN COG standard (tandem); SIOPEN standard (BuMel))
Anti-GD2 antibody (dinutuximab + GM-CSF + isotretinoin; dinutuximab beta in Europe, no IL-2) × 5-6 cycles; then eflornithine maintenance 2 years (US, 2023). (NCCN Dinutuximab: FDA-approved standard; eflornithine: FDA-approved maintenance)
5-6 cycles (COG: topotecan-cyclophosphamide × 2 then cisplatin-etoposide, cyclophosphamide-doxorubicin-vincristine; SIOPEN: rapid COJEC); stem-cell harvest; ANBL1531 adds 131I-MIBG (randomised) or lorlatinib (ALK); ANBL17P1 adds dinutuximab to induction. (NCCN COG ANBL1531 backbone)
A milestone in how this cancer is treated.
Maintenance to reduce relapse risk in high-risk neuroblastoma after ≥PR to prior therapy including anti-GD2
No patient had unacceptable toxicity and none was a feasibility failure over the first five induction cycles with dinutuximab and GM-CSF added.
ORR 63%, CR 33%; 3-year OS 60%.
EFS HR 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Relapsed/refractory high-risk neuroblastoma in bone or bone marrow with partial response, minor response or stable disease, with GM-CSF (accelerated)
ORR 50%.
A milestone in how this cancer is treated.
Dinutuximab beta: high-risk neuroblastoma after induction/transplant; relapsed/refractory disease
Objective response 52.
BuMel > CEM (EFS 50% vs 38%); IL-2 adds no benefit to anti-GD2.
A milestone in how this cancer is treated.
High-risk neuroblastoma after at least partial response to induction, with GM-CSF, IL-2 and isotretinoin
A milestone in how this cancer is treated.
2-year EFS 66% vs 46%; OS 86% vs 75%.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.